[{"NetIncomeLossConverted_1_Q1_USD":53535000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":219801000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":206095000.0,"EarningsPerShareDiluted_1_Q1_USD":0.24,"CommonStockSharesOutstanding_0_Q1_shares":219880198.0,"StockholdersEquity_0_Q1_USD":2727844000.0,"RevenuesConverted_1_Q1_USD":604718000.0,"Assets_0_Q1_USD":3661436000.0,"CommonStockSharesConverted_0_Q1_shares":219880198.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":221867000.0,"EarningsPerShareBasic_1_Q1_USD":0.24,"Ticker":"INCY","CIK":"879169","name":"INCYTE CORP","OfficialName":"Incyte Corp. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"17588712770.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"SP500","filed":"20210504"}]